Skip to content

US · RPID · MEDICAL - DEVICES

Rapid Micro Biosystems, Inc. (RPID) intrinsic value and stock valuation

$0.74as of 2026-11-21 · Mkt cap 95.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rapid Micro Biosystems, Inc. DCF and intrinsic value

InvestorsCraft values RPID with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RPID’s statements →

Rapid Micro Biosystems, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Lexington, MA 02421 rapidmicrobio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$33.6M+15.9% 5y CAGRd
20192025
Net income
-$-47.12M
20192025
Free cash flow
-$-31.91M
20192025
Total equity
$33.2M+6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$33.6M$28.1M$22.5M$17.1M$23.2M
Operating income-$-47.39M-$-49.92M-$-56.56M-$-63.22M-$-47.23M
Net income-$-47.12M-$-46.89M-$-52.47M-$-60.81M-$-73.52M
EPSd-$-1.05M-$-1.08M-$-1.22M-$-1.43M-$-1.77M
Operating cash flow-$-31.06M-$-44.15M-$-45.08M-$-58.55M-$-54.96M
Capital expenditure-$-850K-$-1.36M-$-1.84M-$-6.74M-$-3.22M
Free cash flow-$-31.91M-$-45.52M-$-46.93M-$-65.29M-$-58.18M
Total assets$74.9M$98.2M$143.5M$190.7M$241.2M
Total debt$23.9M$6.17M$7.35M$7.97M$400K
Net debt$3.84M-$-10.74M-$-16.94M-$-19.1M-$-178.39M
Total equity$33.2M$75.4M$118M$164.2M$221M
Cash and short-term investments$38.3M$50.7M$92.1M$108.7M$193.5M
Income statement
20252024202320222021
Revenue$33.6M$28.1M$22.5M$17.1M$23.2M
Cost of revenue$26M$28.2M$28M$25.7M$31M
Gross profit$7.61M-$-110K-$-5.49M-$-8.54M-$-7.74M
Research and development expenses$13.6M$14.6M$12.8M$12.9M$9.78M
Selling, general and administrative expenses$34.8M$35.2M$38.3M$41.8M$29.7M
Other expenses$6.56M$0.00$0.00$0.00$0.00
Operating expenses$55M$49.8M$51.1M$54.7M$39.5M
Cost and expenses$81M$78M$79.1M$80.4M$70.5M
Interest income$1.51M$3.16M$4.21M$1.78M$0.00
Interest expense$1.09M$0.00$0.00$0.00$2.65M
Depreciation and amortization$3.25M$3.36M$3.1M$2.84M$1.53M
Ebitda-$-42.74M-$-43.51M-$-49.33M-$-58.55M-$-69.25M
Operating income-$-47.39M-$-49.92M-$-56.56M-$-63.22M-$-47.23M
Total other income/expenses, net$310K$3.05M$4.13M$1.84M-$-26.2M
Income before tax-$-47.08M-$-46.87M-$-52.44M-$-61.38M-$-73.43M
Income tax expense$40K$20K$30K-$-580K$90K
Net income-$-47.12M-$-46.89M-$-52.47M-$-60.81M-$-73.52M
Weighted average shares outstanding$44.7M$43.6M$43M$42.5M$41.5M
Weighted average diluted shares outstanding$44.7M$43.6M$43M$42.5M$41.5M
Balance sheet
20252024202320222021
Cash and short-term investments$38.3M$50.7M$92.1M$108.7M$193.5M
Net receivables$3.28M$7.53M$5.58M$5.48M$5.63M
Inventory$17.6M$20.2M$20M$21.2M$15.7M
Total current assets$61.2M$80.9M$120.4M$138.6M$218.1M
Property, plant and equipment, net$13.1M$16.4M$19.1M$20.9M$11.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$360K$2.91M$29.8M$9.97M
Total non-current assets$13.7M$17.3M$23M$52.1M$23.1M
Total assets$74.9M$98.2M$143.5M$190.7M$241.2M
Accounts payable$4.14M$2.54M$1.97M$5.43M$3.94M
Short-term debt$1.3M$1.21M$1.13M$770K$0.00
Deferred revenue$4.73M$6.6M$5.97M$4.71M$3.31M
Total current liabilities$18.5M$17.6M$19M$19.1M$18.2M
Long-term debt$22.6M$4.95M$6.21M$7.2M$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$23.2M$5.25M$6.48M$7.43M$2.02M
Capital lease obligations$4.97M$4.95M$7.35M$7.97M$400K
Total liabilities$41.7M$22.8M$25.5M$26.5M$20.2M
Common stock$450K$430K$420K$420K$410K
Retained earnings-$-522.4M-$-475.27M-$-428.38M-$-375.92M-$-315.11M
Accumulated other comprehensive income (loss)$10K$40K-$-100K-$-1.11M-$-20K
Total equity$33.2M$75.4M$118M$164.2M$221M
Total investments$18.3M$34.2M$70.7M$111.4M$25.1M
Total debt$23.9M$6.17M$7.35M$7.97M$400K
Net debt$3.84M-$-10.74M-$-16.94M-$-19.1M-$-178.39M
Cash flow statement
20252024202320222021
Net income-$-47.12M-$-46.89M-$-52.47M-$-60.81M-$-73.52M
Depreciation and amortization$3.25M$3.36M$3.1M$2.84M$1.53M
Stock-based compensation$4.03M$3.87M$4.75M$4.02M$1.84M
Change in working capital$6.06M-$-4.77M$560K-$-5.33M-$-8M
Accounts receivable$4.39M-$-1.99M-$-160K-$-360K-$-20K
Inventory$1.47M-$-340K$1.19M-$-5.84M-$-6.77M
Accounts payable$1.6M$560K-$-3.46M$1.48M-$-520K
Net cash provided by operating activities-$-31.06M-$-44.15M-$-45.08M-$-58.55M-$-54.96M
Investments in property, plant and equipment-$-850K-$-1.36M-$-1.84M-$-6.74M-$-3.22M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$14.3M$36.7M$42.2M-$-93.47M-$-13.29M
Common stock issued$1.1M$240K$0.00$0.00$164.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.8M$200K$150K$690K$216.8M
Net change in cash$3.04M-$-7.37M-$-2.78M-$-151.32M$148.5M
Cash at end of period$20.3M$16.9M$24.6M$27.4M$178.7M
Operating cash flow-$-31.06M-$-44.15M-$-45.08M-$-58.55M-$-54.96M
Capital expenditure-$-850K-$-1.36M-$-1.84M-$-6.74M-$-3.22M
Free cash flow-$-31.91M-$-45.52M-$-46.93M-$-65.29M-$-58.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rapid Micro Biosystems, Inc.

        Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.

        CEO
        Robert G. Spignesi Jr.
        Employees
        171
        Beta
        1.47

        Explore

        Frequently asked questions

        What is the intrinsic value of Rapid Micro Biosystems, Inc. (RPID)?

        InvestorsCraft does not currently publish an intrinsic value for RPID. How the IC value is calculated.

        Is RPID undervalued?

        InvestorsCraft does not publish an undervaluation signal for RPID at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.